{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055645","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.228478+00:00","generated_at":"2026-06-02T12:23:11.817635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs","bullets":["Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.","Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.","DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.","DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.","GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055645","json":"https://secwatch.observer/filing/0000950170-24-055645.json","markdown":"https://secwatch.observer/filing/0000950170-24-055645.md","text":"https://secwatch.observer/filing/0000950170-24-055645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/dsgn-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:23:11.817635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f3b0d7e27f810f0f9bb253cbb15ef20afec6928","claim":"Design Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $11.1 million.","evidence_excerpt":"Net loss was $11.1 million for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$11.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}